According to the "Technical Guidelines for Radioactive Labeled Human Mass Balance Studies" issued by the NMPA, human mass balance studies are an important component of clinical pharmacology research for innovative drugs, and it is recommended that mass balance studies be conducted for all new molecular entities. Therefore, to further clarify the absorption, metabolism, and excretion characteristics of Hydronidone in the human body, a \[¹⁴C\] Hydronidone mass balance study is planned in Chinese healthy adult male participants. This study aims to reveal the pharmacokinetic characteristics of Hydronidone and provide a reference for the rational use of the drug.
Age range
18 Years – 50 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cumulative radioactive recovery in excreta (urine and feces) per collection period
Timeframe: within 9 days after dosing
Cumulative total radioactive recovery in excreta (urine and feces)
Timeframe: within 9 days after dosing
Pharmacokinetic parameters of total radioactivity in plasma : Cmax
Timeframe: within 9 days after dosing
Pharmacokinetic parameters of total radioactivity in plasma : Tmax
Timeframe: within 9 days after dosing
Pharmacokinetic parameters of total radioactivity in plasma : t1/2
Timeframe: within 9 days after dosing
Pharmacokinetic parameters of total radioactivity in plasma : MRT
Timeframe: within 9 days after dosing
Pharmacokinetic parameters of total radioactivity in plasma : AUC
Timeframe: within 9 days after dosing
Whole blood ratio of total radioactivity concentration
Timeframe: within 9 days after dosing
plasma ratio of total radioactivity concentration
Timeframe: within 9 days after dosing
Percentage of unchanged drug relative to total radioactivity exposure in plasma
Timeframe: within 9 days after dosing
Percentage of unchanged drug in urine relative to the administered dose (%Dose)
Timeframe: within 9 days after dosing
Percentage of unchanged drug in feces relative to the administered dose (%Dose)
Timeframe: within 9 days after dosing
Identification of major metabolites in plasma
Timeframe: within 9 days after dosing
Identification of major metabolites in urine
Timeframe: within 9 days after dosing
Identification of major metabolites in feces
Timeframe: within 9 days after dosing